Aerie concludes exclusive license agreement with santen for rhopressa® and rocklatan® in europe and several other regions

Durham, n.c.--(business wire)--aerie pharmaceuticals, inc. (nasdaq: aeri, “aerie”) announced that aerie and santen have entered into an exclusive development and commercialization agreement for rhopressa®/rhokiinsa® (netarsudil ophthalmic solution) 0.02% and rocklatan®/roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. the expanded collaboration includes europe, commonwealth of independent states (cis) countries, china, india, parts of latin america and the oceania countri
AERI Ratings Summary
AERI Quant Ranking